News headlines about Aldeyra Therapeutics (NASDAQ:ALDX) have trended somewhat positive on Friday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.8239789232682 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several research firms have recently issued reports on ALDX. Zacks Investment Research cut Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. ValuEngine raised Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 12th. Canaccord Genuity reissued a “buy” rating and set a $27.00 target price (up from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Cantor Fitzgerald began coverage on Aldeyra Therapeutics in a research note on Tuesday, October 24th. They set an “overweight” rating and a $22.00 target price on the stock. Finally, Cowen reissued an “outperform” rating and set a $14.00 target price (up from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Aldeyra Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.29.
Shares of Aldeyra Therapeutics (ALDX) opened at $6.50 on Friday. The company has a current ratio of 20.35, a quick ratio of 20.35 and a debt-to-equity ratio of 0.02. Aldeyra Therapeutics has a 1 year low of $3.80 and a 1 year high of $11.90.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. equities analysts predict that Aldeyra Therapeutics will post -1.39 earnings per share for the current year.
In other news, major shareholder Life Sciences Maste Perceptive purchased 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 19th. The shares were bought at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 19.04% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-aldeyra-therapeutics-aldx-share-price.html.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.